Long-Term Follow-Up and Overall Survival in NRG258 by Daniela E Matei et al.
Amol Akhade, Senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals, shared on LinkedIn:
“NRG258. CTRT vs CT alone. No Os benifit for III and IVA ca endometrium. Am I missing something here ?
So one side for earlier stages we are adding RT for P53 mutation positive pole negative, saying it is high risk and on other side for higher stages, which definitely have more risk of relapse, no benifit for CTRT? Why so? Are we overselling molecular classification for endometrial cancer based upon retrospective analysis?
Endometrium is only cancer in which retrospective analysis has upgraded the treatment without awaiting prospective validation.
So all eyes on Portec 4a , prospective trial, based upon molecular classification to decide, what’s real benifit of CTRT over RT alone and which patient needs escalation ans who can have de escalation in endometrium cancer.”
Authors: Daniela E Matei et al.
Dr. Amol Akhade is a senior consultant medical oncologist and hemato-oncologist at Suyog Cancer Clinics and Reliance Hospitals. He has received his super specialization training in hemato-oncology and medical oncology from Tata Memorial Hospital.
He specialises in chemotherapy for hematological cancers as well as solid tumors. He also specialises in allogenic and autologous bone marrow transplant
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023